SEC Info℠

Home

Search

My Interests

Help

Sign In

Please Sign In

Biosynergy Inc – ‘10-Q’ for 10/31/19

On:  Monday, 12/16/19, at 3:31pm ET   ·   For:  10/31/19   ·   Accession #:  715812-19-26   ·   File #:  0-12459

Previous ‘10-Q’:  ‘10-Q’ on 9/13/19 for 7/31/19   ·   Next:  ‘10-Q’ on 3/12/20 for 1/31/20   ·   Latest:  ‘10-Q/A’ on 3/28/22 for 1/31/22

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

 Text Wildcards:  ? (any letter/digit),  * (many).  Search Logic:  for Documents:  & (and),  | (or);  for Text:  | (anywhere),  "(&)" (near).  Details... 

  As Of               Filer                 Filing    For·On·As Docs:Size

12/16/19  Biosynergy Inc                    10-Q       10/31/19   41:1.2M

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    132K 
 8: EX-31.1     Certificaton of Chief Executive Officer             HTML     19K 
 9: EX-31.2     Certification of Chief Accounting Officer           HTML     19K 
10: EX-32.1     Certification Pursuant to 18 U.S.C. Section 1350    HTML     14K 
                as Adopted Pursuant to Section 906 of the                        
                Sarbanes-Oxley Act of 2002                                       
11: EX-32.2     Certification Pursuant to 18 U.S.C. Section 1350    HTML     14K 
                as Adopted Pursuant to Section 906 of the                        
                Sarbanes-Oxley Act of 2002                                       
35: R1          Document and Entity Information                     HTML     44K 
22: R2          Balance Sheets (Unaudited)                          HTML    101K 
13: R3          Balance Sheets (Parenthetical)                      HTML     22K 
28: R4          Statements of Operations (Unaudited)                HTML     57K 
34: R5          Statements of Cash Flows (Unaudited)                HTML     65K 
21: R6          Shareholders Equity (Unaudited)                     HTML     24K 
12: R7          Company Organization and Description                HTML     20K 
27: R8          Summary of Significant Accounting Policies          HTML     42K 
36: R9          Inventories                                         HTML     19K 
30: R10         Common Stock                                        HTML     16K 
39: R11         Related Party Transactions                          HTML     25K 
24: R12         Lease Commitments                                   HTML     20K 
15: R13         Customer Concentration                              HTML     20K 
29: R14         Depreciation                                        HTML     16K 
38: R15         Research and Development and Patents                HTML     17K 
23: R16         Summary of Significant Accounting Policies          HTML     88K 
                (Policies)                                                       
14: R17         Summary of Significant Accounting Policies          HTML     23K 
                (Tables)                                                         
31: R18         Inventories (Tables)                                HTML     21K 
37: R19         Related Party Transactions (Tables)                 HTML     23K 
20: R20         Summary of Significant Accounting Policies -        HTML     31K 
                Income Tax Rate (Details)                                        
18: R21         Summary of Significant Accounting Policies -        HTML     24K 
                Provision for Income Taxes (Details)                             
26: R22         Depreciation (Details Narrative)                    HTML     16K 
41: R23         Research and Development and Patents (Details       HTML     17K 
                Narrative)                                                       
19: R24         Inventories - Inventories (Details)                 HTML     23K 
17: R25         Related Party Transactions (Details Narrative)      HTML     22K 
25: R26         Lease Commitments - Future Minimum Lease Expense    HTML     20K 
                (Details)                                                        
40: R27         Customer Concentrations (Details)                   HTML     21K 
16: XML         IDEA XML File -- Filing Summary                      XML     64K 
33: EXCEL       IDEA Workbook of Financial Reports                  XLSX     30K 
 2: EX-101.INS  XBRL Instance -- bsyn-20191031                       XML    240K 
 4: EX-101.CAL  XBRL Calculations -- bsyn-20191031_cal               XML     99K 
 5: EX-101.DEF  XBRL Definitions -- bsyn-20191031_def                XML     59K 
 6: EX-101.LAB  XBRL Labels -- bsyn-20191031_lab                     XML    310K 
 7: EX-101.PRE  XBRL Presentations -- bsyn-20191031_pre              XML    225K 
 3: EX-101.SCH  XBRL Schema -- bsyn-20191031                         XSD     56K 
32: ZIP         XBRL Zipped Folder -- 0000715812-19-000026-xbrl      Zip     41K 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended October 31, 2019

__ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to ___________

Commission file number 0 -12459

Biosynergy, Inc.

(Exact name of registrant as specified in its charter)

Illinois 36-2880990

(State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.)

1940 East Devon Avenue, Elk Grove Village, Illinois 60007 847-956-0471

(Address of principal executive offices) (Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No __

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data file required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files. Yes X No __

Indicate by check mark whether the registrant is a large accelerated filing, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ______ Accelerated filer ______

Non-accelerated filer (Do not check if a smaller reporting company) ______ Smaller reporting company ___X___

Emerging growth company ______

If an emerging growth company, indicated by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes __ No X

APPLICABLE ONLY TO CORPORATE ISSUERS

State the number of shares outstanding of each of the issuer’s classes of common stock, as of October 31, 2019: 14,935,511

BIOSYNERGY, INC.

PART 1 - FINANCIAL INFORMATION

Item 1. Financial Statements and Supplementary Data

BALANCE SHEETS

Assets 

The accompanying notes are an integral part of the financial statements.

BIOSYNERGY, INC.

PART 1 - FINANCIAL INFORMATION 

BALANCE SHEETS

Liabilities and Shareholders’ Equity

The accompanying notes are an integral part of the financial statements

BIOSYNERGY, INC.

Statements of Operations

The accompanying notes are an integral part of the financial statements.

BIOSYNERGY, INC.

STATEMENT OF SHAREHOLDERS' EQUITY

SIX MONTHS ENDED OCTOBER 31, 2019

Common Stock 

The accompanying notes are an integral part of the financial statements.

BIOSYNERGY, INC.

STATEMENTS OF CASH FLOWS

The accompanying notes are an integral part of the financial statements.

BIOSYNERGY, INC.

Notes to Financial Statements

Six Months Ended October 31, 2019 and 2018

Note 1 - Company Organization and Description

In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments, consisting of normal recurring adjustments which are necessary for a fair presentation of the financial position and results of operations for the periods presented. The unaudited condensed financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all the information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America. These condensed financial statements should be read in conjunction with the audited financial statements and notes included in the Company’s April 30, 2019 Annual Report on Form 10-K/A. The results of operations for the six months ended October 31, 2019 are not necessarily indicative of the operating results for the full year.

Biosynergy, Inc. (the Company) was incorporated under the laws of the State of Illinois on February 9, 1976. It is primarily engaged in the development and marketing of medical, consumer and industrial thermometric and thermographic products that utilize cholesteric liquid crystals. The Company’s primary product, the HemoTemp II Blood Monitoring Device, accounted for approximately 91.89% of the sales during the six months ending October 31, 2019 and 90.84% during the six months ending October 31, 2018. The products are sold to hospitals, clinical end-users, laboratories and product dealers located throughout the United States.

Note 2 - Summary of Significant Accounting Policies

The Company maintains all of its cash in various bank deposit accounts, which at times may exceed federally insured limits. No losses have been experienced on such accounts.

Receivables are carried at original invoice less estimates made for doubtful receivables. Management determines the allowances for doubtful accounts by reviewing and identifying troubled accounts on a periodic basis and by using historical experience applied to an aging of accounts. A receivable is considered to be past due if any portion of the receivable balance is outstanding beyond the stipulated due date. Receivables are written off when deemed uncollectible. Recoveries of receivables previously written off are recorded when received.

Inventories are valued at the lower of cost or market using the FIFO (first-in, first-out) method.

Equipment and leasehold improvements are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Repairs and maintenance are charged to expense as incurred; renewals and betterments which significantly extend the useful lives of existing equipment are capitalized. Significant leasehold improvements are capitalized and amortized over the term of the lease; equipment is depreciated over three to ten years.

Depreciation expense was $2,837 and $4,176 for the six month periods ending October 31, 2019 and 2018, respectively.

Prepaid Expenses

Certain expenses, primarily insurance and income taxes, have been prepaid and will be used within one year.

Revenue Recognition

In May 2014, the Financial Accounting Standards Board (FASB) issued an Accounting Standards Update (ASU) 2014-09, "Revenue from Contracts with Customers (Topic 606)", which supersedes the revenue recognition requirements in Accounting Standards Codification (ASC) 605, Revenue Recognition. Several additional ASUs have subsequently been issued amending and clarifying the standard. The core principle of ASU 2014-09 is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance provides a five-step process to achieve that core principle and to determine when and how revenue is recognized. The updates may be applied retrospectively for each period presented or as a cumulative-effect adjustment at the date of adoption.

The Company adopted this standard on May 1, 2018, using the modified retrospective approach. The impact of the adoption of ASU 2014-09 on the Company’s financial statements is as follows:

basis rather than as a net liability. As such, the Company now recognizes a return asset for the right to recover the goods returned by the customer, measured at the former carrying amount of the products, less any expected recovery costs (recorded as an increase to prepaid expenses and other current assets), and a return liability for the amount of expected returns (recorded as an increase to other current liabilities). The Company’s analysis of sales returns over the past several years noted that sales returns are nominal and therefore no sales return allowance is deemed necessary.

There was no adjustment necessary for fiscal year ending April 30, 2018 or prior in relation to the change in the revenue recognition policy and no significant effects on the six month period ending October 31, 2019.

Shipping and Handling

Shipping and handling fees billed to customer, if any, are netted against the related costs which are included in cost of sales. The net cost is not material.

Income Taxes

Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due and deferred taxes related primarily to differences in the methods of accounting for patents, inventories, certain accrued expenses and bad debt expenses for financial and income tax reporting purposes. The deferred income taxes represent the future tax consequences of those differences, which will be taxable in the future.

The Company files tax returns in the U.S. federal jurisdiction and with the state of Illinois. Various tax years remain open to examinations, generally for three years after filing, although there are currently no ongoing tax examinations. Management’s policy is to recognize interest and penalties related to uncertain tax positions in income tax expense.

The provision for income taxes consists of the following components for the six month periods ended October 31:

The differences between the U.S. federal statutory tax rate and the Company’s effective tax rate are as follows:

Research and Development and Patents

Research and development expenditures are charged to operations as incurred. The costs of obtaining patents, primarily legal fees, are capitalized and, once obtained, are amortized over the life of the respective patent on the straight-line method.

Patent amortization expense for the six months ended October 31, 2019 and 2018 were $6,822 and $5,583 respectively.

Patents relate to products that have been developed and are being marketed by the Company. Patents pending relate to products under development.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Income Per Common Share

Income per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Basic and diluted net income per common share is the same for the six months ended October 31, 2019 and 2018 as there are no common stock equivalents.

Comprehensive Income

Components of comprehensive income include amounts that are included in the comprehensive income but are excluded from net income. During the six month periods ending October 31, 2019 and 2018, there were no differences between the Company’s net income and comprehensive income.

Fair Value of Financial Instruments

The Company evaluates its financial instruments based on current market interest rates relative to stated interest rates, length to maturity and the existence of readily determinable market prices. Based on the Company’s analysis, the fair value of financial instruments recorded on the balances sheets as of October 31, 2019 and April 30, 2019, approximates their carrying value. 

Accounting standards have established annual reporting standards for an enterprise’s operating segments and related disclosures about its products, services, geographic areas and major customers. The Company’s operations were a single reportable segment and an international segment. The international segment operations are immaterial. See Note 7.

Recent Accounting Pronouncements

The FASB issues ASUs to amend the authoritative literature in ASC. There have been a number of ASUs to date that amend the original text of ASCs. Those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company or (iv) are not expected to have a significant impact on the Company.

Note 3 – Inventories

Components of inventories are as follows:

Note 4 – Common Stock

The Company’s common stock is traded in the over-the-counter market. However, there is no established public trading market due to limited and sporadic trades. The Company’s common stock is not listed on a recognized market or stock exchange.

Note 5 - Related Party Transactions

The Company and its affiliates are related through common stock ownership as follows as of October 31, 2019:

Stock of Affiliates 

As of October 31, 2019, $19,699 was due from F. K. Suzuki International, Inc. These balances result from an allocation of common expenses charged to FKSI prior to April 30, 2006 offset by advances received from time to time. No interest income is received or accrued by the Company. The financial condition of FKSI is such that it will unlikely be able to repay the Company during the next year without liquidating a portion of its assets, including a portion of its ownership in the Company. As a result, the receivable balance has been reclassified as a contra equity account since April 30, 2006.

A board member provided a variety of legal services to the Company in his capacity as a partner in a law firm. Fees for such legal services were approximately $7,585 and $14,811 for the six months ended October 31, 2019 and 2018 respectively.

Note 6 – Lease Commitments

On February 25, 2016, the FASB issued Topic 842, Leases. Under its core principle, a lessee will recognize lease assets and liabilities on the balance sheet for all arrangements with terms longer than 12 months. Lessor accounting remains largely consistent with existing U.S. GAAP. At inception, a lessee must classify all leases as either finance or operating. In February 2018, the Company entered into a two-year lease agreement for its current facilities, which started May 1, 2018 and expires on April 30, 2020. Under the new lease standard, which was early-adopted by the Company as of May 1, 2018, the Company’s lease was accounted for as an operating lease. As a result, the Company measured the lease liability using the two year term and rates per the lease agreement and recognized a lease liability, with a corresponding right-of-use asset. A discount was not calculated due to the lease agreement only having a two year term.

The operating lease expense, recorded as an amortization expense, for the six months ending October 31, 2019 is $44,550. The actual lease liability payment for the six months ending October 31, 2019 was $45,100. Retrospective application of the new standard did not render any adjustments since all of the Company’s operating leases were less than one year.

Maturities of lease liabilities as of October 31, 2019 are presented in the following table:

Year Ending April 30:

2020 $ 44,550

Note 7 – Customer Concentrations

Shipments to one customer amounted to 26.95% of sales during the first six months of Fiscal 2020 compared to 30.53% during the comparative Fiscal 2019 period. As of October 31, 2019, there were outstanding accounts receivable from this customer of $73,825 compared to $55,423 at October 31, 2018. Shipments to another customer amounted to 37.10% of sales during the first six months of Fiscal 2020 and 35.66% of sales during the first six months of Fiscal 2019. As of October 31, 2019, there were outstanding accounts receivable from this customer of $134,288 compared to $127,278 at October 31, 2018.

The Company had export sales of $15,295 during the 2^nd Quarter of Fiscal 2020, and export sales of $32,865 during the 2^nd Quarter of Fiscal 2019. For the six months ending October 31, 2019 export sales were $22,605 and $43,655 for the same period ending October 31, 2018. The Company also believes that some of its medical devices were sold to distributors within the United States who resold the devices in foreign markets. However, the Company does not have any information regarding such sales and such sales are not considered to be material.

BIOSYNERGY, INC.

Six Months Ended October 31, 2019 and 2018

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Net Sales/Revenues

For the three month period ending October 31, 2019 (“2nd Quarter”), the net sales decreased 4.91%, or $16,126, and decreased 2.66%, or $17,173, during the six month period ending October 31, 2019, as compared to net sales for the comparative periods ending in 2018. This decrease in sales is primarily the result of a decrease in the sales of HemoTemp^®, HemoTemp^® II and TempTrend^® products. As of October 31, 2019, the Company had no back orders.

In addition to the above, the Company had $630 and $1,260 of other miscellaneous revenues primarily from interest income and leasing a portion of its storage space to a third party during the three and the six month periods ending October 31, 2019, respectively.

Costs and Expenses

General

The operating expenses of the Company during the 2nd Quarter decreased overall by 2.26%, or $4,172, and decreased by 1.53%, or $5,901, for the six month period ending October 31, 2019, as compared to the same periods ending in 2018. The decrease during the 2^nd Quarter and for the six month period ending October 31, 2019 was due to a decrease in legal and advertising fees.

Cost of Sales

The overall cost of sales during the 2nd Quarter increased by $668 and increased by $3,928 during the six month period ending October 31, 2019 as compared to the same periods ending in 2018. For the six months ended October 31, 2019, the increase was due to higher employee costs and higher raw material costs. As a percentage of sales, the cost of sales were 34.76% during the 2nd Quarter and 32.85% for the comparative quarter ending in 2018; and 34.29% during the six month period ending October 31, 2019 compared to 32.77% in 2018. It is not anticipated that the cost of sales as a percentage of sales will materially change in the near future.

Research and Development Expenses

Research and Development costs increased $264, or .68%, during the 2nd Quarter as compared to the same quarter in 2018. These costs increased by $3,265, or 4.31%, during the six month period ending October 31, 2019 as compared to the same period in 2018. This increase was primarily due to higher employee costs.

Marketing Expenses

Marketing expenses for the 2nd Quarter decreased by $4,499, or 9.32%, as compared to the quarter ending October 31, 2018 and decreased by $2,405 or 2.56%, during the six month period ending October 31, 2019 compared to the six-month period ending October 31, 2018. The change in marketing expenses for the six-month period ending October 31, 2019 compared to the six-month period ending October 31, 2018 was primarily due to lower advertising fees and lower health insurance costs.

General and Administrative Expenses

General and administrative costs increased by $63, or .06%, in the 2nd Quarter, and decreased by $6,761, or 3.15%, during the six month period ending October 31, 2019, as compared to the same periods in 2018. This overall decrease for the six months ending October 31, 2019 was due primarily to lower legal fees and a decrease in healthcare costs. Except for unforeseen items and ordinary cost increases, it is unlikely general and administrative expenses will materially change during the remainder of Fiscal 2020.

Net Income

The Company realized a net income of $16,990 during the 2nd Quarter as compared to a net income of $25,997 for the comparative quarter in the prior year. The Company also realized a net income of $25,568 for the six month period ending October 31, 2019 as compared to a net income of $36,376 during the same period in 2018. The decrease in net income is a result of decreased net sales for the six month period ending October 31, 2019.

Assets /Liabilities

General

Since April 30, 2019, the Company’s assets have decreased by $37,878 and liabilities have decreased by $63,446. The overall decrease in assets and liabilities is primarily due to the changes in the accounting treatment for leases, which include amortization of the right of use asset and payments against the lease liability.

Related Party Transactions

The Company was owed $19,699 by F.K. Suzuki International, Inc. ("FKSI"), an affiliate, at October 31, 2019 and April 30, 2019. This account primarily represents common expenses which were previously charged by the Company to FKSI for reimbursement. No interest is received or accrued by the Company. Collectability of the amounts due from FKSI cannot be assured without the liquidation of all or a portion of its assets, including a portion of its common stock of the Company. As a result, the amount owed by FKSI to the Company is classified as a reduction of FKSI’s capital in the Company.

A board member provides a variety of legal services to the Company in his capacity as a partner in a law firm. Fees for such legal services were approximately $7,585 and $14,811 for the six months ended October 31, 2019 and 2018, respectively.

Current Assets/Liabilities Ratio

The ratio of current assets to current liabilities, 17.9 to 1, has increased compared to 10.5 to 1 at April 30, 2019, primarily due to higher cash balances and lower accrued liabilities and lower operating lease liability. The Company anticipates the ratio of current assets to current liabilities will remain substantially at its current level as a result of the change in accounting methods, subject to other normal fluctuations. In order to maintain or improve the Company’s asset/liabilities ratio, the Company’s operations must remain profitable.

Liquidity and Capital Resources

During the six month period ending October 31, 2019, the Company experienced an increase in working capital of $79,777. This was primarily due to higher cash balances and lower accrued liabilities and lower operating lease liability.

The Company has attempted to conserve working capital whenever possible. To this end, the Company attempts to keep inventory at minimum levels. The Company believes that it will be able to maintain adequate inventory to supply its customers on a timely basis by careful planning and forecasting demand for its products. However, the Company is nevertheless required to carry a minimum amount of inventory to meet the delivery requirements of customers and thus, inventory represents a substantial portion of the Company’s investment in current assets.

The Company presently grants payment terms to customers and dealers. Although the Company experiences varying collection periods of its account receivable, the Company believes that uncollectable accounts receivable will not have a significant effect on future liquidity.

The cash provided by operating activities was $44,045 during the six month period ending October 31, 2019. There was no cash used in investing activities. Except for its operating capital, limited equipment purchases and patent prosecution costs, management is not aware of any other material capital requirements or material contingencies for which it must provide. There were no cash flows from financing or investing activities during the six month period ending October 31, 2019.

As of October 31, 2019, the Company had $1,663,155 of current assets available. Of this amount, $39,836 was prepaid expenses, $156,959 was inventory, $242,190 was net trade receivables and $1,224,170 was cash. The Company’s available cash and cash flow are considered adequate to fund the short-term capital needs of the Company. The Company does not have a working line of credit, and does not anticipate obtaining a working line of credit in the near future. Thus there is a risk additional financing may be necessary to fund long-term capital needs of the Company, although there is no such currently known long-term capital needs other than operations.

 Effects of Inflation. With the exception of inventory, labor costs and product sales prices increasing with inflation, inflation has not had a material effect on the Company’s revenues and income from continuing operations in the past three years. Inflation is not expected to have a material effect in the foreseeable future.

Critical Accounting Policies and Estimates. On December 12, 2001, the SEC issued FR-60 “Cautionary Advice Regarding Disclosure About Critical Accounting Policies.” FR-60 is an intermediate step to alert companies to the need for greater investor awareness of the sensitivity of financial statements to the methods, assumptions, and estimates underlying their preparation, including the judgments and uncertainties affecting the application of those policies and the likelihood that materially different amounts would be reported under different conditions or using different assumptions.

The Company’s significant accounting policies are disclosed in Note 2 to the Financial Statements for the 2nd Quarter. See “Financial Statements.” Except as noted below, the impact on the Company’s financial position or results of operation would not have been materially different had the Company reported under different conditions or used different assumptions. The policies which may have materially affected the financial position and results of operations of the Company if such information had been reported under different circumstances or assumptions are: none.

Use of Estimates. Preparation of financial statements and conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the Financial Statements and the reported amounts of revenues and expenses during the reporting period. The financial condition of the Company and results of operations may differ from the estimates and assumptions made by management in preparation of the Financial Statements accompanying this report.

Allowance for Bad Debts. The Company periodically performs credit evaluations of its customers and generally does not require collateral to support amounts due from the sale of its products. The Company maintains an allowance for doubtful accounts based on its best estimate of accounts receivable.

Forward-Looking Statements

This report may contain statements which, to the extent they are not recitations of historical fact, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). Such forward-looking statements involve risks and uncertainties. Actual results may differ materially from such forward-looking statements for reasons including, but not limited to, changes to and developments in the legislative and regulatory environments effecting the Company’s business, the impact of competitive products and services, changes in the medical and laboratory industries caused by various factors, risks inherit in marketing new products, as well as other factors as set forth in this report. Thus, such forward-looking statements should not be relied upon to indicate the actual results which might be obtained by the Company. No representation or warranty of any kind is given with respect to the accuracy of such forward-looking information. The forward-looking information has been prepared by the management of the Company and has not been reviewed or compiled by independent public accountants.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Market risk is the risk of loss arising from adverse changes in market rates and prices, such as interest rates, foreign currency exchange rates and commodity prices. The Company’s primary exposure to market risk is interest rate risk associated with its short term money market investments. The Company does not have any financial instruments held for trading or other speculative purposes and does not invest in derivative financial instruments, interest rate swaps or other investments that alter interest rate exposure. The Company does not have any credit facilities with variable interest rates. The Company’s operations are not exposed to financial risk that will have a material impact on its financial position and results of operation.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

The Company has established and maintains disclosure controls and procedures (as defined in Rules 13a15(e) and 15d-15(e) of the Exchange Act) which are controls and other procedures of the Company that are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms.

Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its Chief Executive Officer and Chief Accounting Officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. The Company’s Chief Executive Officer and Chief Accounting Officer have evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, the Company’s Chief Executive Officer and its Chief Accounting Officer have concluded that the Company’s disclosure controls and procedures were effective.

There have been no changes in the Company’s internal control over financial reporting during the Company’s Fiscal Quarter ending October 31, 2019 that have materially affected or are likely to materially affect the Company’s internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings.

As of the end of the Company’s Fiscal Quarter ending October 31, 2019, there are no material pending legal proceedings to which the Company or any of its subsidiaries is a party to of which any of their property is the subject.

Item 1A. Risk Factors.

In addition to the other information set forth in this report on Form 10-Q, you should also consider the factors, risks and uncertainties which could materially affect the Company’s business, financial condition or future results as discussed in Part I, Item 1A – “Risk Factors” of our Annual Report on Form 10-K/A for the fiscal year ended April 30, 2019. There were no significant changes to the risk factors identified on the Form 10-K/A for the fiscal year ended April 30, 2019 or during the second quarter of Fiscal 2020.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

During the past three years, the Company has not sold securities which were not registered under the Securities Act.

Item 3. Defaults Upon Senior Securities.

(b)             As of the end of the Company’s Fiscal Quarter ending October 31, 2019, there have been no material arrearages in the payment of dividends and there has been no other material delinquency not cured within 30 days, with respect to any class of preferred stock of the Company which is registered or which ranks prior to any class of registered securities, or with respect to any class of preferred stock of any significant subsidiary of the Company.

Item 4. Mine Safety Disclosures.

The disclosures required by this Item are not applicable to the Company.

Item 5. Other Information.

Item 6. Exhibits.

The following exhibits are filed as a part of this report:

(15)        Letter regarding unaudited interim financial information - none.

(24)          Power of Attorney - none.

(i) Incorporated by reference to a Registration Statement filed on Form S-18 with the Securities and Exchange Commission, 1933 Act Registration Number 2-38015C, under the Securities Act of 1933, as amended, and Incorporated by reference, with regard to Amended and Restated By-Laws, to the Company’s Current Statement on Form 8-K dated as of July 2, 2009 filed with the Securities and Exchange Commission.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Biosynergy, Inc. 

---

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing		Date		Other Filings
		4/30/20		10-K
Filed on:		12/16/19
For Period end:		10/31/19
		5/1/19
		4/30/19		10-K,  10-K/A
		10/31/18		10-Q,  10-Q/A
		5/1/18
		4/30/18		10-K
		2/25/16
		7/2/09		8-K
		4/30/06		10KSB
		12/12/01
				List all Filings

↑Top

---

Filing Submission 0000715812-19-000026   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

---

---

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Wed., Apr. 24, 1:23:17.1pm ET